News >

Shah Shares Immunotherapy, STAT3 Inhibitor Data in GI Cancers

Brandon Scalea
Published: Wednesday, Aug 08, 2018

Manish A. Shah, MD
Manish A. Shah, MD
Two clinical trials presented at the 2018 ASCO Annual Meeting addressed unmet needs for select with patients with gastrointestinal (GI) cancers; however, a number of challenges remain, explained Manish A. Shah, MD.

, Shah, director of Gastrointestinal Oncology and chief of Solid Tumor Service at Weill Cornell Medicine/NewYork-Presbyterian Hospital, shared insight on the challenges that remain in the treatment of esophageal and gastric cancers.

OncLive: Please provide some background to the KEYNOTE-180 trial.

Shah: Esophageal cancer is a deadly disease. Unfortunately, most patients with metastatic disease die within 1 year. There are very few targeted therapies in esophageal cancer and most patients don't get treatment after the second line of therapy. The active cytotoxic drugs have modest activity, but we are really in search for more. It's certainly an unmet need.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication